- Trillium Therapeutics (TRIL) has dosed its first patient in Phase 1b study of TTI-622 in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
- TTI-622 is a fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumours
- Preclinical studies have shown that TTI-622 exhibits anti-myeloma activity as a monotherapy that is enhanced when combined with proteasome inhibitors
- Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer
- Trillium Therapeutics Inc. (TRIL) is down 5.75 per cent and is trading at USD$8.69 at 3:14 pm ET
Trillium Therapeutics (TRIL) has dosed its first patient in Phase 1b study of TTI-622 in combination with carfilzomib and dexamethasone.
TTI-622 is a fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumours.
CD47 binds to SIRPα on macrophages and delivers a “don’t eat me” signal that inhibits the ability of macrophages to engulf and destroy cancer cells.
Preclinical studies have shown that TTI-622 exhibits anti-myeloma activity as a monotherapy that is enhanced when combined with proteasome inhibitors.
“With the dosing of this patient we have begun an exciting new phase of development for TTI-622,” commented Dr. Ingmar Bruns, Trillium’s Chief Medical Officer.
“This is the first patient to receive TTI-622 in combination with another anti-cancer agent, and we are eager to build upon the monotherapy activity that we have observed in multiple hematologic cancers,” added Bruns.
The combination of TTI-622 and carfilzomib plus dexamethasone is being assessed as part of the ongoing, open-label Phase 1a/1b study.
Approximately 30 relapsed/refractory multiple myeloma patients who have received at least 3 prior lines of therapy which must include a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody will be enrolled.
The primary endpoints are safety and overall response rate.
“Despite the development of new therapeutics and combinations, there remains a significant unmet medical need for myeloma patients who relapse after earlier lines of therapy,” added Dr. Bruns.
“We believe that the combination of TTI-622 and carfilzomib plus dexamethasone has strong potential to address the unmet need and have a significant impact on the myeloma treatment landscape if approved,” concluded Dr. Bruns.
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer.
Trillium Therapeutics Inc. (TRIL) is down 5.75 per cent and is trading at USD$8.69 at 3:14 pm ET.